{"id":{"repo_id":"cornell","oai_identifier":"oai:ecommons.cornell.edu:1813/116276"},"canonical_url":"https://search.ndltd.org/etd/cornell/oai:ecommons.cornell.edu:1813/116276","repository":{"repo_id":"cornell","name":"Cornell University","base_url":"https://ecommons.cornell.edu/server/oai/request"},"display":{"title":"DEVELOPMENT OF A LIPID NANOPARTICLE-ENCAPSULATED mRNA VACCINE AGAINST CLOSTRIDIUM DIFFICILE INFECTION","abstract":"Clostridium difficile (C. difficile) infection (CDI) is a significant health risk within hospital settings. C. difficile is an anaerobic gram-positive bacterium that spreads among people via the fecal-oral route. It forms spores and produces toxins in vivo, leading to hospital-acquired diarrhea and colitis, particularly in developed countries. The emergence and proliferation of C. difficile are likely due to the widespread use of antibiotics. This work proposed to develop a lipid nanoparticle-encapsulated, nucleoside-modified mRNA (mRNA-LNP) vaccine against CDI. The mRNA encoded one truncated fragment of the receptor binding domain (RBD) of C. difficile Toxin A. We assessed both humoral and cell-mediated immune responses in mice following immunization. Results showed that the vaccine induced strong humoral and cell-mediated immune responses. By conducting a spore challenge, we confirmed that the robust immune responses provided protection against CDI. This research highlights the potential for creating highly effective mRNA vaccines against bacterial pathogens and serves as a foundational model for future antibacterial mRNA vaccines.","abstract_html":"Clostridium difficile (C. difficile) infection (CDI) is a significant health risk within hospital settings. C. difficile is an anaerobic gram-positive bacterium that spreads among people via the fecal-oral route. It forms spores and produces toxins in vivo, leading to hospital-acquired diarrhea and colitis, particularly in developed countries. The emergence and proliferation of C. difficile are likely due to the widespread use of antibiotics. This work proposed to develop a lipid nanoparticle-encapsulated, nucleoside-modified mRNA (mRNA-LNP) vaccine against CDI. The mRNA encoded one truncated fragment of the receptor binding domain (RBD) of C. difficile Toxin A. We assessed both humoral and cell-mediated immune responses in mice following immunization. Results showed that the vaccine induced strong humoral and cell-mediated immune responses. By conducting a spore challenge, we confirmed that the robust immune responses provided protection against CDI. This research highlights the potential for creating highly effective mRNA vaccines against bacterial pathogens and serves as a foundational model for future antibacterial mRNA vaccines.","abstract_has_math":false,"creators":["Hu, Yuping"],"institution":"Cornell University","degree_name":"M.S., Materials Science and Engineering","degree_level":"Master of Science","degree_discipline":"Materials Science and Engineering","degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":["Jiang, Shaoyi"],"committee_members":["Yang, Rong"],"year":2024,"date_issued":"2024-08","date_published":"2024-08","updated_at":"2026-11-19T03:11:32Z","subjects":[],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.doi","label":"DOI","values":["https://doi.org/10.7298/f6v1-0k58"],"render_values":[{"text":"https://doi.org/10.7298/f6v1-0k58","href":"https://doi.org/10.7298/f6v1-0k58","code":true}]},{"key":"dc:identifier.bibid","label":"Dc Identifier Bibid","values":["16611819"],"render_values":[{"text":"16611819","href":null,"code":true}]},{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["ProQuest Submission ID: 12261","ProQuest Publication ID: 31489134"],"render_values":[{"text":"ProQuest Submission ID: 12261","href":null,"code":true},{"text":"ProQuest Publication ID: 31489134","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/1813/116276","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/1813/116276","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://ecommons.cornell.edu/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aecommons.cornell.edu%3A1813%2F116276","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.chair","label":"Chair","values":["Jiang, Shaoyi"]},{"key":"dc:contributor.committeemember","label":"Committee Member","values":["Yang, Rong"]},{"key":"dc:creator","label":"Author","values":["Hu, Yuping"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2025-01-14T19:39:33Z"]},{"key":"dc:date.issued","label":"Date","values":["2024-08"]},{"key":"dc:relation.uri","label":"Dc Relation URI","values":["https://newcatalog.library.cornell.edu/catalog/16611819"]},{"key":"dc:type","label":"Dc Type","values":["dissertation or thesis"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Materials Science and Engineering"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Master of Science"]},{"key":"thesis:degree_name","label":"Degree Name","values":["M.S., Materials Science and Engineering"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Cornell University"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.bibid","label":"Dc Identifier Bibid","values":["16611819"]},{"key":"dc:identifier.doi","label":"DOI","values":["https://doi.org/10.7298/f6v1-0k58"]},{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["ProQuest Submission ID: 12261","ProQuest Publication ID: 31489134"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/1813/116276"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"cerif:openaire","label":"Cerif Openaire","values":["<Publication xmlns=\"https://www.openaire.eu/cerif-profile/1.1/\" id=\"3af2ef0f-70c8-4c3c-a903-9b4e9751a771\"> <Type xmlns=\"https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types\">http://purl.org/coar/resource_type/c_1843</Type> <Language>en</Language> <Title>DEVELOPMENT OF A LIPID NANOPARTICLE-ENCAPSULATED mRNA VACCINE AGAINST CLOSTRIDIUM DIFFICILE INFECTION</Title> <PublishedIn> <Publication> </Publication> </PublishedIn> <PublicationDate>2024-08</PublicationDate> <DOI>https://doi.org/10.7298/f6v1-0k58</DOI> <Authors> <Author> <DisplayName>Hu, Yuping</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <OrgUnit /> </Publisher> </Publishers> <Abstract>Clostridium difficile (C. difficile) infection (CDI) is a significant health risk within hospital settings. C. difficile is an anaerobic gram-positive bacterium that spreads among people via the fecal-oral route. It forms spores and produces toxins in vivo, leading to hospital-acquired diarrhea and colitis, particularly in developed countries. The emergence and proliferation of C. difficile are likely due to the widespread use of antibiotics. This work proposed to develop a lipid nanoparticle-encapsulated, nucleoside-modified mRNA (mRNA-LNP) vaccine against CDI. The mRNA encoded one truncated fragment of the receptor binding domain (RBD) of C. difficile Toxin A. We assessed both humoral and cell-mediated immune responses in mice following immunization. Results showed that the vaccine induced strong humoral and cell-mediated immune responses. By conducting a spore challenge, we confirmed that the robust immune responses provided protection against CDI. This research highlights the potential for creating highly effective mRNA vaccines against bacterial pathogens and serves as a foundational model for future antibacterial mRNA vaccines.</Abstract> <Access xmlns=\"http://purl.org/coar/access_right\" > </Access> </Publication>"]},{"key":"cris:virtual.author","label":"Cris Virtual Author","values":["Hu, Yuping"]},{"key":"cris:virtualsource.collection","label":"Cris Virtualsource Collection","values":["5893a6ea-7af3-41d7-abc6-04bcd26ab5df"]},{"key":"dc:description","label":"Description","values":["29 pages"]},{"key":"dc:description.abstract","label":"Abstract","values":["Clostridium difficile (C. difficile) infection (CDI) is a significant health risk within hospital settings. C. difficile is an anaerobic gram-positive bacterium that spreads among people via the fecal-oral route. It forms spores and produces toxins in vivo, leading to hospital-acquired diarrhea and colitis, particularly in developed countries. The emergence and proliferation of C. difficile are likely due to the widespread use of antibiotics. This work proposed to develop a lipid nanoparticle-encapsulated, nucleoside-modified mRNA (mRNA-LNP) vaccine against CDI. The mRNA encoded one truncated fragment of the receptor binding domain (RBD) of C. difficile Toxin A. We assessed both humoral and cell-mediated immune responses in mice following immunization. Results showed that the vaccine induced strong humoral and cell-mediated immune responses. By conducting a spore challenge, we confirmed that the robust immune responses provided protection against CDI. This research highlights the potential for creating highly effective mRNA vaccines against bacterial pathogens and serves as a foundational model for future antibacterial mRNA vaccines."]},{"key":"dc:description.collection","label":"Dc Description Collection","values":["Cornell Theses and Dissertations"]},{"key":"dc:format.mimetype","label":"Dc Format Mimetype","values":["application/pdf"]},{"key":"dcterms:license","label":"Dcterms License","values":["https://hdl.handle.net/1813/59810.2"]},{"key":"dc:title","label":"Title","values":["DEVELOPMENT OF A LIPID NANOPARTICLE-ENCAPSULATED mRNA VACCINE AGAINST CLOSTRIDIUM DIFFICILE INFECTION"]},{"key":"dspace:entity.type","label":"Dspace Entity Type","values":["Publication"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"cerif:openaire":["<Publication xmlns=\"https://www.openaire.eu/cerif-profile/1.1/\" id=\"3af2ef0f-70c8-4c3c-a903-9b4e9751a771\"> <Type xmlns=\"https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types\">http://purl.org/coar/resource_type/c_1843</Type> <Language>en</Language> <Title>DEVELOPMENT OF A LIPID NANOPARTICLE-ENCAPSULATED mRNA VACCINE AGAINST CLOSTRIDIUM DIFFICILE INFECTION</Title> <PublishedIn> <Publication> </Publication> </PublishedIn> <PublicationDate>2024-08</PublicationDate> <DOI>https://doi.org/10.7298/f6v1-0k58</DOI> <Authors> <Author> <DisplayName>Hu, Yuping</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <OrgUnit /> </Publisher> </Publishers> <Abstract>Clostridium difficile (C. difficile) infection (CDI) is a significant health risk within hospital settings. C. difficile is an anaerobic gram-positive bacterium that spreads among people via the fecal-oral route. It forms spores and produces toxins in vivo, leading to hospital-acquired diarrhea and colitis, particularly in developed countries. The emergence and proliferation of C. difficile are likely due to the widespread use of antibiotics. This work proposed to develop a lipid nanoparticle-encapsulated, nucleoside-modified mRNA (mRNA-LNP) vaccine against CDI. The mRNA encoded one truncated fragment of the receptor binding domain (RBD) of C. difficile Toxin A. We assessed both humoral and cell-mediated immune responses in mice following immunization. Results showed that the vaccine induced strong humoral and cell-mediated immune responses. By conducting a spore challenge, we confirmed that the robust immune responses provided protection against CDI. This research highlights the potential for creating highly effective mRNA vaccines against bacterial pathogens and serves as a foundational model for future antibacterial mRNA vaccines.</Abstract> <Access xmlns=\"http://purl.org/coar/access_right\" > </Access> </Publication>"],"cris:virtual.author":["Hu, Yuping"],"cris:virtualsource.collection":["5893a6ea-7af3-41d7-abc6-04bcd26ab5df"],"dc:contributor.chair":["Jiang, Shaoyi"],"dc:contributor.committeemember":["Yang, Rong"],"dc:creator":["Hu, Yuping"],"dc:date.accessioned":["2025-01-14T19:39:33Z"],"dc:date.issued":["2024-08"],"dc:description":["29 pages"],"dc:description.abstract":["Clostridium difficile (C. difficile) infection (CDI) is a significant health risk within hospital settings. C. difficile is an anaerobic gram-positive bacterium that spreads among people via the fecal-oral route. It forms spores and produces toxins in vivo, leading to hospital-acquired diarrhea and colitis, particularly in developed countries. The emergence and proliferation of C. difficile are likely due to the widespread use of antibiotics. This work proposed to develop a lipid nanoparticle-encapsulated, nucleoside-modified mRNA (mRNA-LNP) vaccine against CDI. The mRNA encoded one truncated fragment of the receptor binding domain (RBD) of C. difficile Toxin A. We assessed both humoral and cell-mediated immune responses in mice following immunization. Results showed that the vaccine induced strong humoral and cell-mediated immune responses. By conducting a spore challenge, we confirmed that the robust immune responses provided protection against CDI. This research highlights the potential for creating highly effective mRNA vaccines against bacterial pathogens and serves as a foundational model for future antibacterial mRNA vaccines."],"dc:description.collection":["Cornell Theses and Dissertations"],"dc:format.mimetype":["application/pdf"],"dc:identifier.bibid":["16611819"],"dc:identifier.doi":["https://doi.org/10.7298/f6v1-0k58"],"dc:identifier.other":["ProQuest Submission ID: 12261","ProQuest Publication ID: 31489134"],"dc:identifier.uri":["https://hdl.handle.net/1813/116276"],"dc:language.iso":["en"],"dc:relation.uri":["https://newcatalog.library.cornell.edu/catalog/16611819"],"dcterms:license":["https://hdl.handle.net/1813/59810.2"],"dc:title":["DEVELOPMENT OF A LIPID NANOPARTICLE-ENCAPSULATED mRNA VACCINE AGAINST CLOSTRIDIUM DIFFICILE INFECTION"],"dc:type":["dissertation or thesis"],"dspace:entity.type":["Publication"],"others:access_status":["open.access"],"thesis:degree_discipline":["Materials Science and Engineering"],"thesis:degree_level":["Master of Science"],"thesis:degree_name":["M.S., Materials Science and Engineering"],"thesis:institution_name":["Cornell University"]},"updated_at":"2026-11-19T03:11:32Z"}